Human Stem Cell Institute - detailes

Details

Name	Human Stem Cell Institute

« Back to the placement page

Issuer news

24.03.2022
Cbonds: ACRA affirms Human Stem Cell Institute at "BB+(RU)" (ACRA national rating scale for the Russian Federation credit rating); outlook stable
30.07.2021
Cbonds: Human Stem Cell Institute announces about increased RAS net profit for 6 months of 2021 equal to RUB 60.07 million. Total revenue’s increase is 33.88%
06.04.2021
Cbonds: RAS. Human Stem Cell Institute. December 31, 2020: long-term liabilities’ increase is 5.11 % YoY
25.03.2021
Cbonds: ACRA assigns "BB+(RU)" (ACRA national rating scale for the Russian Federation credit rating) to Human Stem Cell Institute; outlook stable
05.06.2020
Cbonds: Rusgrain Holding’s, Human Stem Cell Institute’s 1 Q 2020 Y RAS results were published
22.07.2019
Cbonds: First Collection Bureau’s, ALROSA-Nurba’s, Human Stem Cell Institute’s RAS results were published

This site uses cookies to make your browsing experience more convenient and personal. Cookies store useful information on your computer to help us improve the efficiency and relevance of our site for you. In some cases, they are essential to making the site work properly. By accessing this site, you consent to the use of cookies.

Ok